If you have been on antidepressants that did not work, the experience tends to leave a particular kind of mark. It is not simply the disappointment of a medication not delivering what it promised. It is the waiting — weeks of side effects, of hope held carefully and then quietly set aside. It is the conversation where you report back that it is not helping, the dose adjustment, another wait, another assessment, and the creeping fear that this is simply how things are for you. By the second or third medication that has not worked, the narrative that takes hold — “I am someone who doesn’t respond to treatment” — is not just emotionally painful. It actively delays getting real help. We want to be clear with you at Vigeo Wellness: that narrative is almost certainly wrong. What you may actually have is treatment-resistant depression, a well-defined clinical entity, and there are specific interventions designed for it that are meaningfully different from another SSRI.
What Treatment-Resistant Depression Actually Is
Treatment-resistant depression (TRD) is defined in clinical practice as major depressive disorder that has not responded to at least two adequate antidepressant trials, with adequate dose and adequate duration. That last qualifier matters: an “adequate trial” means sufficient dose for sufficient time — typically six to eight weeks at therapeutic levels. Patients who stopped a medication early due to side effects, or who were undertreated on dose, may not technically meet the TRD definition even if the medication felt like it didn’t work (Gaynes et al., 2020; McIntyre et al., 2023).
That said, the number of people who genuinely meet TRD criteria is substantial. The STAR*D trial — one of the largest and most rigorous studies of antidepressant effectiveness ever conducted — found that remission rates fell as more treatment steps were required, with lower remission rates after later medication changes and higher relapse rates during follow-up. This is not a rare edge case. It is a common, recognized clinical reality, and the patients experiencing it deserve options that match the severity of their situation (Rush et al., 2006). If you are curious about how depression is typically approached before reaching the TRD threshold, our overview of how depression is treated provides useful background.
Why Another Antidepressant Is Often Not the Answer
There is a point at which prescribing a third or fourth antidepressant without a different rationale becomes unlikely to produce a different outcome. SSRIs and SNRIs share overlapping mechanisms — they target monoamine reuptake. If your brain’s response to monoamine modulation has been inadequate across multiple trials, the probability that another medication in the same class will produce remission may be lower. This is not a criticism of those medications — they work extraordinarily well for many people. But for patients with true TRD, continuing to try variations of the same approach while expecting different results is not serving you well.
This is why TRD-specific interventions exist. SPRAVATO® (esketamine), IV ketamine therapy, and TMS therapy each target depression through mechanisms that are different from conventional antidepressants. They were developed specifically because the need for alternative mechanisms in treatment-resistant populations was clinically recognized. When something hasn’t worked, the answer is not necessarily more of it — sometimes it is something fundamentally different. For a deeper look at the evidence behind one of these alternatives, our post on the benefits of SPRAVATO® for treatment-resistant depression is worth reading.
SPRAVATO® — FDA-Approved for TRD
SPRAVATO® (esketamine) nasal spray is an FDA-approved pharmacological treatment specifically indicated for treatment-resistant depression. This is an important distinction. FDA approval for TRD means that SPRAVATO® completed randomized controlled trials in TRD populations and was shown to be effective and safe under defined conditions. The pivotal trials demonstrated significant improvement in depressive symptoms compared to placebo in patients who had not responded to prior antidepressants, including studies of SPRAVATO® used alongside a newly initiated oral antidepressant (Daly et al., 2018; Popova et al., 2019; U.S. Food and Drug Administration, 2019; U.S. National Library of Medicine, n.d.).
SPRAVATO® works through the glutamatergic system — specifically NMDA receptor modulation — which is an entirely different mechanism from SSRIs and SNRIs. It is administered as a nasal spray in our office, and you are monitored following each session as required by the FDA’s REMS safety program. Treatment involves an induction phase of twice-weekly sessions, followed by a maintenance schedule. Results vary by individual, and we will not overstate what the data shows. But for patients with documented TRD, this is a treatment backed by one of the most rigorous regulatory pathways available. For patients who want to better understand the appointment experience itself, our guide to what SPRAVATO® feels like offers a closer look.
IV Ketamine — A Closely Related Option
IV ketamine infusions, offered at our Weatherford location, use the same family of chemistry as SPRAVATO® but via intravenous administration and with a slightly different pharmacological profile. Ketamine infusions for depression are considered off-label — ketamine does not have an FDA indication specifically for depression in the way SPRAVATO® does — but the clinical evidence base for IV ketamine in TRD is substantial. Studies consistently demonstrate rapid antidepressant effects, often within hours of infusion, in patients who have not responded to conventional antidepressants (Krystal et al., 2019; Murrough et al., 2013; Walsh et al., 2022).
The speed of ketamine’s antidepressant effect is one of its most clinically meaningful properties. For patients who have been waiting months or years for adequate relief, the possibility of meaningful symptom improvement within days of beginning a ketamine series is significant. This does not mean the effects are permanent without ongoing support — maintenance strategies are an important part of any ketamine treatment plan — but the rapid onset addresses an urgent need that conventional medications simply cannot match.
Discuss your specific history with your provider to understand whether IV ketamine or SPRAVATO® is the more appropriate starting point for your situation. Both are available at Vigeo Wellness in Weatherford, and we can walk through the considerations together.
TMS Therapy — Non-Medication, FDA-Cleared
For patients who want to avoid medications entirely or who have not tolerated pharmacological treatments well, TMS therapy offers a third pathway. TMS (transcranial magnetic stimulation) is FDA-cleared for major depressive disorder, and it works through a completely different mechanism than any medication: focused magnetic pulses are delivered to specific regions of the brain’s prefrontal cortex, stimulating neural circuits associated with mood regulation. TMS does not involve anesthesia, does not require any medication, and has no systemic side effects (Cohen et al., 2022; McClintock et al., 2018).
TMS treatment is typically administered five days per week for four to six weeks. Sessions are conducted in our office and take approximately thirty to forty minutes. Patients remain awake and alert throughout and can drive themselves to and from appointments. The most commonly reported side effects are mild scalp discomfort at the treatment site and occasional headache, both of which typically diminish after the first several sessions. TMS is FDA-cleared, and insurance coverage is often available for patients with a documented diagnosis of MDD who have not responded to at least one antidepressant. To learn more about what TMS has shown in clinical practice, our post on TMS therapy for depression covers the evidence in detail.
The barrier we hear most often around TMS is the time commitment — daily sessions for several weeks can feel logistically impossible for patients who are working or managing family responsibilities. We try to work with Weatherford patients on scheduling within the constraints they have, because we believe that a treatment you can actually attend is better than a perfect protocol you cannot access.
A Realistic Conversation About What We Can Offer
We want to be honest with you about something that we think matters: none of these treatments — SPRAVATO®, IV ketamine, or TMS — are guaranteed to work for every patient. Treatment-resistant depression is resistant in part because it is heterogeneous; what drives it differs from person to person, and the response to any given intervention reflects that complexity. Results vary by individual, and we will not promise outcomes we cannot guarantee.
What we can offer is a genuine evaluation, a treatment team that takes your history seriously, and access to the most evidence-based interventions currently available for TRD in one place, without requiring you to travel beyond Parker County. We can also offer continuity — our therapy and psychiatry services in Weatherford remain involved in your care whether you pursue SPRAVATO®, ketamine, TMS, or some combination, and we coordinate care so that nothing falls through the cracks.
Our Fort Worth office at 817-634-5521 also offers the same full range of TRD treatments if that location is more convenient for any of your appointments.
Frequently Asked Questions
How do I know if I have treatment-resistant depression?
Clinically, TRD is generally defined as MDD that has not responded to at least two adequate antidepressant trials. If you have tried two or more antidepressants at appropriate doses for at least six to eight weeks without achieving remission, you may meet the criteria. We review your full medication history during consultation to make this assessment carefully, because the quality of prior trials matters and not every “medication that didn’t work” represents an adequate trial.
Should I try SPRAVATO® or IV ketamine first?
Both are reasonable options for TRD. SPRAVATO® has FDA approval specifically for this indication, which can matter for insurance coverage, and it is self-administered as a nasal spray under supervision. IV ketamine has a longer evidence base in research terms but is off-label for depression. The choice often depends on your insurance situation, your specific symptom picture, how quickly you need to see improvement, and your own preferences. We discuss this together during your evaluation.
Can I pursue ketamine or SPRAVATO® and TMS at the same time?
This is a clinical question that requires individualized assessment. Some providers use combination approaches, and there is emerging evidence that combining treatments may enhance outcomes for some patients. We evaluate each patient’s full picture before making any recommendation about concurrent therapies. Discuss your situation with your provider so we can look at your specific history.
What if none of these treatments work?
We will not abandon you at that point. If initial interventions do not produce the response hoped for, we reassess, we look at what we may have missed diagnostically, we consider whether dosing or protocol needs adjustment, and we explore whether additional options are worth evaluating. Treatment-resistant depression requires persistence on the part of both patient and provider. We are committed to staying in that process with you.
Is TRD different from bipolar depression?
Yes — and the distinction matters clinically. Some patients who are diagnosed with TRD may actually have bipolar depression that has been unrecognized, which requires a different treatment approach. This is part of why our intake evaluation is thorough. We screen carefully for bipolar spectrum illness, because misdiagnosis is not rare, and treating bipolar depression with antidepressant monotherapy or with certain other interventions carries specific risks. Getting the diagnosis right is foundational.
Key Takeaways
- Treatment-resistant depression is a defined clinical entity — failure of at least two adequate antidepressant trials — affecting a meaningful share of patients with major depression.
- Continuing to try additional antidepressants of the same class after multiple failures may be less likely to produce remission; TRD often requires interventions with different mechanisms.
- SPRAVATO® (esketamine) is FDA-approved for TRD; IV ketamine is supported by substantial clinical evidence and is off-label; TMS therapy is FDA-cleared for MDD — all three are available at Vigeo Wellness in Weatherford.
- Results vary by individual — we will not promise guaranteed outcomes, but we offer a genuine evaluation, honest communication, and continuity of care.
- Vigeo Wellness in Weatherford is one of the few locations in Parker County where all three of these TRD-specific interventions are available in one practice.
You have been trying. That is not nothing — it is evidence of how much you want your life back. At Vigeo Wellness in Weatherford, we think you deserve a team that matches that effort with something genuinely different. Call us at 817-672-9407 or contact Vigeo Wellness to schedule a consultation. Let’s look at your history together and find out what the right next step actually is. You are heard. You matter.
References
Cohen, S. L., Bikson, M., Badran, B. W., & George, M. S. (2022). A visual and narrative timeline of US FDA milestones for transcranial magnetic stimulation devices in clinical care. Brain Stimulation, 15(1), 73–75. https://doi.org/10.1016/j.brs.2021.11.010
Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H. K., & Drevets, W. C. (2018). Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry, 75(2), 139–148. https://doi.org/10.1001/jamapsychiatry.2017.3739
Gaynes, B. N., Lux, L., Lloyd, S., Hansen, R. A., Gartlehner, G., Thieda, P., Brode, S., Evans, T. S., Viswanathan, M., Lohr, K. N., & Trivedi, M. H. (2020). Defining treatment-resistant depression. Depression and Anxiety, 37(2), 134–145. https://doi.org/10.1002/da.22968
Krystal, J. H., Abdallah, C. G., Sanacora, G., Charney, D. S., & Duman, R. S. (2019). Ketamine: A paradigm shift for depression research and treatment. Neuron, 101(5), 774–778. https://doi.org/10.1016/j.neuron.2019.02.005
McClintock, S. M., Reti, I. M., Carpenter, L. L., McDonald, W. M., Dubin, M., Taylor, S. F., Cook, I. A., O’Reardon, J., Husain, M. M., Wall, C., Krystal, A. D., Sampson, S. M., Morales, O., Nelson, B. G., Latoussakis, V., George, M. S., Lisanby, S. H., & National Network of Depression Centers rTMS Task Group. (2018). Consensus recommendations for the clinical application of repetitive transcranial magnetic stimulation in the treatment of depression. Journal of Clinical Psychiatry, 79(1), 16cs10905. https://doi.org/10.4088/JCP.16cs10905
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., Ly-Uson, J., Mansur, R. B., McAllister-Williams, R. H., Murrough, J. W., Nemeroff, C. B., Nierenberg, A. A., Rosenblat, J. D., Sanacora, G., Schatzberg, A. F., Shelton, R. C., Stahl, S. M., Trivedi, M. H., Vieta, E., Vinberg, M., Williams, N., Young, A. H., & Maj, M. (2023). Treatment-resistant depression: Definition, prevalence, detection, management, and investigational interventions. World Psychiatry, 22(3), 394–412. https://doi.org/10.1002/wps.21120
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., Charney, D. S., & Mathew, S. J. (2013). Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial. American Journal of Psychiatry, 170(10), 1134–1142. https://doi.org/10.1176/appi.ajp.2013.13030392
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., Molero, P., Vieta, E., Bajbouj, M., Manji, H., Drevets, W. C., & Singh, J. B. (2019). Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: A randomized double-blind active-controlled study. American Journal of Psychiatry, 176(6), 428–438. https://doi.org/10.1176/appi.ajp.2019.19020172
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., McGrath, P. J., Rosenbaum, J. F., Sackeim, H. A., Kupfer, D. J., Luther, J., & Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. American Journal of Psychiatry, 163(11), 1905–1917. https://doi.org/10.1176/ajp.2006.163.11.1905
SPRAVATO® REMS. (n.d.). SPRAVATO® REMS. https://www.spravatorems.com/
U.S. Food and Drug Administration. (2019). FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic. https://web.archive.org/web/20190501183937/https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified
U.S. National Library of Medicine. (n.d.). DailyMed: SPRAVATO—esketamine hydrochloride solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d81a6a79-a74a-44b7-822c-0dfa3036eaed
Walsh, Z., Mollaahmetoglu, O. M., Rootman, J., Golsof, S., Keeler, J., Marsh, B., Nutt, D. J., & Morgan, C. J. A. (2022). Ketamine for the treatment of mental health and substance use disorders: Comprehensive systematic review. BJPsych Open, 8(1), e19. https://doi.org/10.1192/bjo.2021.1061
Medical Disclaimer
The information in this blog is for educational purposes only and does not constitute medical advice. SPRAVATO® (esketamine) is a prescription medication approved for adults with treatment-resistant depression and should only be pursued under the supervision of a licensed provider familiar with your full medical and psychiatric history. Ketamine infusion therapy for depression is an off-label use. TMS therapy is FDA-cleared for major depressive disorder and should be pursued only after clinical evaluation. Individual results vary. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room.